sb 202190 has been researched along with Carcinoma, Epidermoid in 2 studies
4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole: structure given in first source; inhibits p38 MAP kinase
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 2 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Ko, JC | 1 |
Chiu, HC | 1 |
Wo, TY | 1 |
Huang, YJ | 1 |
Tseng, SC | 1 |
Huang, YC | 1 |
Chen, HJ | 1 |
Syu, JJ | 1 |
Chen, CY | 1 |
Jian, YT | 1 |
Jian, YJ | 1 |
Lin, YW | 1 |
Hill, NT | 1 |
Zhang, J | 1 |
Leonard, MK | 1 |
Lee, M | 1 |
Shamma, HN | 1 |
Kadakia, M | 1 |
2 other studies available for sb 202190 and Carcinoma, Epidermoid
Article | Year |
---|---|
Inhibition of p38 MAPK-dependent MutS homologue-2 (MSH2) expression by metformin enhances gefitinib-induced cytotoxicity in human squamous lung cancer cells.
Topics: Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Cell Survival; Chemotherapy, Adjuvan | 2013 |
1α, 25-Dihydroxyvitamin D₃ and the vitamin D receptor regulates ΔNp63α levels and keratinocyte proliferation.
Topics: Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Cell Survival | 2015 |